NanoStraw delivery brings a membrane carrying hollow nanostructures into contact with cells so that payloads pass directly into the cytoplasm, avoiding the viral vectors used by transduction and the high field strengths used by bulk electroporation.
Nanostraw delivery suits primary cells and other hard-to-transfect cell types while limiting the viability loss associated with bulk methods, which is the property the company presents for cell engineering and therapeutic applications.
Intracellular delivery tools are used across cell and gene therapy development, where payloads such as plasmid DNA, messenger RNA, proteins and gene-editing complexes have to reach cell types that resist conventional transfection.
Suppliers in this segment include instrument and reagent vendors addressing the same hard-to-transfect applications, so competing on delivery efficiency and cell viability matters more than scale.
NAVAN Technologies is an early-stage life-science tools company based in San Carlos, California, that develops the NanoStraw platform for delivering macromolecules into hard-to-transfect cells.
The company was founded in 2017 and has raised seed-stage funding. The platform supports cell engineering, therapeutic development and basic research, and the company takes enquiries rather than selling products for direct purchase.
